K J Somaiya Hospital develops 10-minute tests to bridge India’s haemophilia diagnosis gap

These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000

Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy

Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies

The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio

Vir Biotechnology advances VIR-5500 into expansion trials in prostate cancer

Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial

Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors

Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study

AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial

Highlights Mirvetuximab-based regimen promise

Chiba University study flags allergy risk in high-binding antibody drugs

For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market